dc.contributor.authorChandrasekharan, Prashant
dc.contributor.authorYang, Chang-Tong
dc.contributor.authorNasrallah, Fatima Ali
dc.contributor.authorTay, Hui Chien
dc.contributor.authorChuang, Kai-Hsiang
dc.contributor.authorRobins, Edward G.
dc.date.accessioned2016-03-23T07:23:40Z
dc.date.available2016-03-23T07:23:40Z
dc.date.issued2015
dc.identifier.citationChandrasekharan, P., Yang, C.-T., Nasrallah, F. A., Tay, H. C., Chuang, K.-H., & Robins, E. G. (2015). Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model. Contrast Media & Molecular Imaging, 10(3), 237-244.en_US
dc.identifier.issn1555-4309en_US
dc.identifier.urihttp://hdl.handle.net/10220/40315
dc.description.abstractPharmacokinetics of Gd(DO3A-Lys), a macrocyclic gadolinium based MRI contrast agent functionalized with a lysine derivative, was studied in Wistar rats. Kinetic data was fitted using a two compartment model and revealed Gd(DO3A-Lys) to have a distribution half-life, t1/2(alpha), of 1.3 min, an elimination half-life, t1/2(beta), of 24.9 min and a large volume of distribution, VD, of 0.49 L/kg indicative of the agent being able to rapidly distribute into tissues and organs. Contrast enhanced magnetic resonance angiography (CEMRA) in an orthotopic U87MG glioma mouse model demonstrated considerable enhancement of both the tumor and surrounding vasculature after intravenous administration of Gd(DO3A-Lys). Applying dynamic contrast enhanced magnetic resonance imaging (DCEMRI) in the glioma of different sizes further showed distinct uptake characteristics and patterns of enhancement, which suggests the potential for differentiating changes at different stages of tumor growth. Our results indicate that Gd(DO3A-Lys) could be a promising candidate for glioma MR imaging.en_US
dc.description.sponsorshipASTAR (Agency for Sci., Tech. and Research, S’pore)en_US
dc.format.extent26 p.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesContrast Media & Molecular Imagingen_US
dc.rights© 2015 John Wiley & Sons, Ltd. This is the author created version of a work that has been peer reviewed and accepted for publication by Contrast Media and Molecular Imaging, John Wiley & Sons, Ltd. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1002/cmmi.1634].en_US
dc.subjectgadolinium chelateen_US
dc.subjectmagnetic resonance imaging (MRI)en_US
dc.subjectpharmacokineticsen_US
dc.subjectcontrast agenten_US
dc.subjecttumor diagnosisen_US
dc.subjectorthotopic glioma modelen_US
dc.titlePharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor modelen_US
dc.typeJournal Article
dc.contributor.schoolLee Kong Chian School of Medicine
dc.identifier.doihttp://dx.doi.org/10.1002/cmmi.1634
dc.description.versionAccepted versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record